Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

3期 提前终止 NCT03794583

摘要

This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623). This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)(RIN-PH-304).

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

Up to 4 years · Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and — University of Tennessee Graduate School of Medicine
• Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster — Chiesi Farmaceutici S.p.A.
• Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®T — Chiesi Farmaceutici S.p.A.
• Tiotropium/Salmeterol Inhalation Powder in COPD — Boehringer Ingelheim
• Risk Factors, Costs, and Impacts of ED Boarding — University of Maryland, Baltimore
• Anti-Platelets in Chronic Obstructive Pulmonary Disease — Brigham and Women's Hospital

全部试验